Jump to content

Avastin (bevacizumab) has minimal impact on castrate resistant prostate cancer


JimJimJimJim

Recommended Posts

JimJimJimJim

Jim Marshall (not a doctor) said ...

Avastin (bevacizumab) is a monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for certain metastatic cancers, including combination use with standard chemotherapy for metastatic colon cancer, certain lung cancers, renal cancers, and glioblastoma multiforme of the brain.

It looked like a worthwhile thing to try it with prostate cancer.

Unfortunately, the trial reported below with men with non-metastatic castrate resistant prostate cancer showed it had minimal impact on the disease course.

Another one bites the dust!

... end Jim

ISRN Oncol. 2012;2012:242850. Epub 2012 Jun 13.

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer.

Ogita S, Tejwani S, Heilbrun L, Fontana J, Heath E, Freeman S, Smith D, Baranowski K, Vaishampayan U.

Source

Department of Oncology, Wayne State University and Karmanos Cancer Center, Detroit, MI 48201, USA.

Abstract

Introduction/Background. Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state. The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients. Patients. Patients with prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases and PSA progression despite androgen deprivation therapy. Methods. Bevacizumab 10 mg/kg intravenously was administered every 14 days until PSA progression, development of metastasis, or unacceptable toxicity. Results. 15 patients were enrolled and treated with bevacizumab for a median duration of 3.1 months. Median baseline PSA was 27 ng/mL, and seven patients had Gleason Score ≥8. Five patients had declined in PSA during the treatment. Median PSA doubling time was prolonged from 4.7 months pretreatment to 6.5 months. Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively. There were three grade 3 adverse events (one proteinuria and two hypertension) and one pulmonary embolism. There was no treatment-related mortality. Conclusion. Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC, and investigation of novel strategies is needed.

PMID: 22745916

This extract can be found on http://PubMed.com, and is in the public domain.

On PubMed.com there will be a link to the full paper (often $30, sometimes free).

Any highlighting (except the title) is not by the author, but by Jim Marshall.

Jim is not a doctor.

Link to post
Share on other sites

Archived

This topic is now archived and is closed to further replies.

×
×
  • Create New...